Join
Live feed
·
PRReleasevia Quantisnow
TuHURA Biosciences Inc. logo

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

ByQuantisnow·Wall Street's wire, on your screen.
HURA· TuHURA Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HURA (TuHURA Biosciences Inc.) and more on Quantisnow.